Lucosky Brookman LLP represented Nordicus Partners Corporation (Nasdaq: NORD) as company counsel in connection with its successful uplisting from the OTCQB Market to the Nasdaq Capital Market.
Nordicus Partners, a biotechnology company focused on developing innovative therapeutics for diseases with unmet medical needs, announced that its common stock had been approved for listing on Nasdaq, with trading expected to commence on October 30, 2026, under its existing ticker symbol, “NORD.”
The uplisting represents a significant milestone for Nordicus Partners as it advances its biotechnology portfolio, including therapeutic development programs targeting oral disorders.
